RT Journal Article
T1 Factors associated with the number of drugs in darunavir/cobicistat regimens.
A1 Martinez, Esteban
A1 Negredo, Eugenia
A1 Knobel, Hernando
A1 Ocampo, Antonio
A1 Sanz, José
A1 Garcia-Fraile, Lucio
A1 Martin-Carbonero, Luz
A1 Lozano, Fernando
A1 González-Doménech, Carmen María
A1 Gutierrez, Mar
A1 Montero, Marta
A1 Boix, Vicente
A1 Payeras, Antoni
A1 Torralba, Miguel
A1 González-Cordón, Ana
A1 Alejos, Belén
A1 Pérez-Elías, María Jesús
K1 SIDA -  Tratamiento
K1 Infecciones por VIH - Tratamiento
K1 Mononucleosis - Tratamiento
K1 Agentes antivíricos
AB Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy.Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens.Methods: A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48 weeks were compared according to the number of drugs used.Results: There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA <50 copies/mL and 88% had ≥200 CD4 cells/mm3) who initiated darunavir/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged <50 years, with prior AIDS and darunavir plus ritonavir use, and with CD4 cells <200/mm3 and with detectable viral load at initiation of darunavir/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens.Discussion: Darunavir/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription.
PB Oxford University Press
YR 2019
FD 2019-10-05
LK https://hdl.handle.net/10630/28953
UL https://hdl.handle.net/10630/28953
LA spa
NO Martinez E, Negredo E, Knobel H, Ocampo A, Sanz J, Garcia-Fraile L, Martin-Carbonero L, Lozano F, Gonzalez-Domenech CM, Gutierrez M, Montero M, Boix V, Payeras A, Torralba M, Gonzalez-Cordon A, Moreno A, Alejos B, Perez-Elias MJ; GeSIDA 9316 CODAR Study Group. Factors associated with the number of drugs in darunavir/cobicistat regimens. J Antimicrob Chemother. 2020 Jan 1;75(1):208-214. doi: 10.1093/jac/dkz399.
NO The CODAR study (Gesida Study no 9316) was sponsored by Sociedad Española de Enfermedades Infecciosas y Microbiología-Grupo de Estudio del SIDA (SEIMC-GESIDA). This work was supported by Janssen Cilag S.A. and Red de Investigacion en Sida (RIS): RIS-EST29 and RD12/0017/0001, RD12/0017/0005, RD17/0017/0022 and RD17/0017/0029.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026